IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDEAYA Biosciences (NASDAQ: IDYA) has appointed Joshua Bleharski, Ph.D. as Chief Financial Officer, expected to transition into the role by early May. Dr. Bleharski joins from J.P. Morgan, where he served as Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group for nearly 17 years.
During his tenure at J.P. Morgan, Dr. Bleharski advised on financing and strategic transactions exceeding $65 billion in value for biotechnology companies. The company currently has 6 potential first-in-class clinical programs and 3 preclinical programs in development across multiple solid tumor indications.
Dr. Bleharski's background includes positions as Senior Staff Scientist at a private biotechnology company and post-doctoral fellowships at LIAI and UCLA School of Medicine. He holds a BS in Biology from Duke University, a Ph.D. in Immunology from UCLA, and an MBA from UC Berkeley's Haas School of Business.
IDEAYA Biosciences (NASDAQ: IDYA) ha nominato Joshua Bleharski, Ph.D. come Chief Financial Officer, con il passaggio previsto per l'inizio di maggio. Il Dr. Bleharski proviene da J.P. Morgan, dove ha ricoperto il ruolo di Managing Director e Co-Head Globale della Biopharma nel gruppo di Healthcare Investment Banking per quasi 17 anni.
Durante il suo mandato in J.P. Morgan, il Dr. Bleharski ha prestato consulenza su finanziamenti e transazioni strategiche che superano i 65 miliardi di dollari in valore per le aziende biotecnologiche. L'azienda attualmente ha 6 programmi clinici potenzialmente innovativi e 3 programmi preclinici in fase di sviluppo su diverse indicazioni di tumori solidi.
Il background del Dr. Bleharski include posizioni come Senior Staff Scientist in un'azienda biotecnologica privata e borse post-dottorato presso LIAI e la UCLA School of Medicine. Ha conseguito una laurea in Biologia presso la Duke University, un dottorato in Immunologia presso la UCLA e un MBA presso la Haas School of Business dell'UC Berkeley.
IDEAYA Biosciences (NASDAQ: IDYA) ha nombrado a Joshua Bleharski, Ph.D. como Director Financiero, con la transición esperada para principios de mayo. El Dr. Bleharski se une de J.P. Morgan, donde se desempeñó como Director General y Co-Líder Global de Biopharma en el grupo de Banca de Inversión en Salud durante casi 17 años.
Durante su tiempo en J.P. Morgan, el Dr. Bleharski asesoró en financiación y transacciones estratégicas que superan los 65 mil millones de dólares en valor para las empresas de biotecnología. La compañía actualmente tiene 6 programas clínicos potencialmente pioneros y 3 programas preclínicos en desarrollo en múltiples indicaciones de tumores sólidos.
La experiencia del Dr. Bleharski incluye puestos como Científico Superior en una empresa de biotecnología privada y becas postdoctorales en LIAI y la Escuela de Medicina de UCLA. Tiene una licenciatura en Biología de la Universidad de Duke, un doctorado en Inmunología de UCLA y un MBA de la Haas School of Business de UC Berkeley.
IDEAYA 바이오사이언스 (NASDAQ: IDYA)는 조슈아 블레하르스키 박사를 최고재무책임자로 임명했으며, 5월 초에 이 역할로 전환될 예정이다. 블레하르스키 박사는 J.P. 모건에서 근무했으며, 17년 가까이 헬스케어 투자은행 그룹의 생명공학 부문 관리 이사이자 글로벌 공동 책임자로 활동했다.
J.P. 모건 재직 동안 블레하르스키 박사는 생명공학 회사에 대해 650억 달러를 초과하는 자금 조달 및 전략적 거래에 대해 자문을 제공했다. 회사는 현재 1등급의 잠재적 임상 프로그램 6개와 3개의 전임상 프로그램을 다양한 고형 종양 적응증에 대해 개발 중이다.
블레하르스키 박사의 배경에는 개인 생명공학 회사의 수석 직원 과학자 직위와 LIAI 및 UCLA 의과대학의 박사후 연구원직이 포함된다. 그는 듀크 대학교에서 생물학 학사, UCLA에서 면역학 박사, UC 버클리 하스 경영대학원에서 MBA를 취득했다.
IDEAYA Biosciences (NASDAQ: IDYA) a nommé Joshua Bleharski, Ph.D. au poste de directeur financier, avec une transition prévue début mai. Le Dr Bleharski rejoint J.P. Morgan, où il a été directeur général et co-responsable mondial de Biopharma dans le groupe de banque d'investissement en santé pendant près de 17 ans.
Au cours de son mandat chez J.P. Morgan, le Dr Bleharski a conseillé sur des financements et des transactions stratégiques dépassant 65 milliards de dollars pour des entreprises de biotechnologie. L'entreprise a actuellement 6 programmes cliniques potentiellement de première classe et 3 programmes précliniques en développement pour de multiples indications de tumeurs solides.
Le parcours du Dr Bleharski comprend des postes de chercheur senior dans une entreprise de biotechnologie privée et des bourses postdoctorales à LIAI et à l'UCLA School of Medicine. Il est titulaire d'une licence en biologie de l'Université Duke, d'un doctorat en immunologie de l'UCLA et d'un MBA de la Haas School of Business de l'UC Berkeley.
IDEAYA Biosciences (NASDAQ: IDYA) hat Joshua Bleharski, Ph.D. zum Chief Financial Officer ernannt, der voraussichtlich Anfang Mai die Rolle übernehmen wird. Dr. Bleharski kommt von J.P. Morgan, wo er fast 17 Jahre als Managing Director und Global Co-Head der Biopharma im Healthcare Investment Banking tätig war.
Während seiner Zeit bei J.P. Morgan beriet Dr. Bleharski in Finanzierungs- und strategischen Transaktionen im Wert von über 65 Milliarden Dollar für Biotechnologieunternehmen. Das Unternehmen hat derzeit 6 potenziell bahnbrechende klinische Programme und 3 präklinische Programme in Entwicklung über mehrere solide Tumorindikationen.
Dr. Bleharskis Werdegang umfasst Positionen als Senior Staff Scientist bei einem privaten Biotechnologieunternehmen und Postdoc-Stipendien an LIAI und der UCLA School of Medicine. Er hat einen BS in Biologie von der Duke University, einen Ph.D. in Immunologie von der UCLA und einen MBA von der Haas School of Business der UC Berkeley.
- Appointment of seasoned financial executive with 17 years of investment banking experience
- New CFO brings expertise in transactions valued over $65 billion
- Company has robust pipeline with 6 clinical and 3 preclinical programs in development
- None.
"We are ecstatic to welcome Josh to IDEAYA as we advance our broad potential first-in-class precision medicine oncology pipeline and build a fully integrated biotechnology company. Josh is a highly accomplished finance executive, with extensive corporate finance, strategy, public financing, and strategic transactions experience that will be invaluable as we drive forward our vision to build the industry leading precision medicine oncology company," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
"I am thrilled to be joining IDEAYA during this exciting phase of growth as the company advances 6 potential first-in-class clinical programs and 3 preclinical programs through IND-enabling studies across multiple solid tumor indications. I look forward to working alongside their team of talented, dedicated professionals to realize our collective vision of building a leading precision medicine oncology company focused on scientific innovation and addressing high unmet medical needs in cancer," said Dr. Bleharski.
Prior to IDEAYA, Dr. Bleharski served as a Managing Director and Global Co-Head of Biopharma with J.P. Morgan's Healthcare Investment Banking group. Over the course of his banking career he advised on numerous financing and strategic transactions representing more than
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements related to the company's advancement of its clinical and pre-clinical programs and potential commercialization of its products. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-appointment-of-healthcare-investment-banking-veteran-joshua-bleharski-as-chief-financial-officer-302371661.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When will Joshua Bleharski start as CFO at IDEAYA Biosciences (IDYA)?
How many clinical programs does IDEAYA Biosciences (IDYA) currently have in development?
What was Joshua Bleharski's previous position before joining IDEAYA (IDYA)?
What is the total value of transactions Dr. Bleharski advised on during his banking career?
